drugset / Trial / NCT01046786
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord
Phase 1/2
Completed
8 enrolled
China Spinal Cord Injury Network
Chinese University of Hong Kong · collabThe University of Hong Kong · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
Timeline
- Start
- 2010-01
- Primary completion
- 2013-10
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lithium | Unknown | — | Oral |
| Comparator | Methylprednisolone | Other / unclassified | 30 mg/kg | Intravenous |
| Comparator | Umbilical Cord Blood Mononuclear Cell | Cell therapy | 1.6e+06 cells | Other |
| Comparator | Umbilical Cord Blood Mononuclear Cell | Cell therapy | 3.2e+06 cells | Other |
| Comparator | Umbilical Cord Blood Mononuclear Cell | Cell therapy | 6.4e+06 cells | Other |